for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Mithra Pharmaceuticals SA

MITRA.BR

Latest Trade

24.96EUR

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

18.12

 - 

32.96

As of on the Euronext Brussels ∙ Minimum 15 minute delay

Pricing

Previous Close
24.96
Open
--
Volume
--
3M AVG Volume
1.31
Today's High
--
Today's Low
--
52 Week High
32.96
52 Week Low
18.12
Shares Out (MIL)
37.69
Market Cap (MIL)
940.72
Forward P/E
58.97
Dividend (Yield %)
--

Next Event

Mithra Pharmaceuticals SA Annual Shareholders Meeting

Latest Developments

More

Mithra Pharmaceuticals Initiates Phase III Clinical Program For Donesta

Mithra Provides Supplementary Details On Estelle® Us Deal With Mayne

Mithra Pharmaceuticals Renegotiates Earnout Payments

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Mithra Pharmaceuticals SA

Mithra Pharmaceuticals SA is a Belgium-based company active in the pharmaceutical industry. The Company is dedicated to provide products and services for the fertility, contraception and menopause of women. It has a number of patent families regarding Estetrol (E4), a natural estrogen produced by the human foetus, which enables the investigation of fertility and contraception products. Mithra is focused on the development of two late-stage E4-based products: Estelle, a 5th generation oral contraceptive, and Donesta, a hormone therapy for Vasomotor Symptoms in menopause. Mithra develops a contraceptive vaginal ring called Myring and Zoreline, a biodegradable subcutaneous implant for hormone dependant cancer.

Industry

Biotechnology & Drugs

Contact Info

Rue Saint-Georges 5

+32.4.3492822

https://www.mithra.com/

Executive Leadership

Marc Coucke

Non-Executive Chairman of the Board Representing Alychlo NV

Francois Fornieri

Chief Executive Officer, Chief Business Development Officer, Executive Director - Representative of YIMA SPRL

Christophe Marechal

Chief Financial Officer - Representing CMM&C SPRL

Patrick Kellens

Chief Information Officer

Graham K. Dixon

Chief Scientific Officer

Key Stats

2.00 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2016

0.0K

2017

0.0K

2018

0.1K

2019(E)

0.1K
EPS (EUR)

2016

-1.130

2017

-1.370

2018

-0.340

2019(E)

0.423
Price To Earnings (TTM)
--
Price To Sales (TTM)
13.30
Price To Book (MRQ)
14.71
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
420.38
LT Debt To Equity (MRQ)
393.80
Return on Investment (TTM)
-28.45
Return on Equity (TTM)
-25.64

Latest News

Latest News

BRIEF-Mithra Pharmaceuticals Potential New Perimenopause Product Launch In 2023

* MITHRA ANNOUNCED ON MONDAY POTENTIAL FOR NEW PERIMENOPAUSE PRODUCT CANDIDATE PERINESTA LAUNCH AS EARLY AS 2023

BRIEF- Mithra Pharmaceuticals Provides Update On Its Key Programmes

* US/CANADA PHASE III ARM OF ESTELLE® ORAL CONTRACEPTION DUE TO COMPLETE IN Q4 2018

BRIEF-Mithra Announces Last Subject Visit In Estelle Phase III Study In EU/Russia

* MITHRA ANNOUNCES LAST SUBJECT VISIT IN ESTELLE® PHASE III STUDY IN EU/RUSSIA AND COMPLETION OF ENDOMETRIAL SUBSTUDY

BRIEF-Mithra Pharmaceuticals Announces Positive Donesta Phase IIb Study

* ANNOUNCES POSITIVE DONESTA PHASE IIB STUDY ACHIEVING PRIMARY OBJECTIVE AND CONFIRMING PROMISING SAFETY PROFILE

BRIEF-Mithra Pharmaceuticals Signs Principle Agreement For Estelle Commercialization In Canada With Searchlight Pharma

* SIGNS PRINCIPLE AGREEMENT FOR ESTELLE COMMERCIALIZATION IN CANADA WITH SEARCHLIGHT PHARMA

BRIEF-Mithra Pharmaceuticals Applies For Additional Estelle® Patent Based On Positive Hemostasis Data

* MITHRA APPLIES FOR ADDITIONAL ESTELLE® PATENT BASED ON POSITIVE HEMOSTASIS DATA

BRIEF-Mithra Pharmaceuticals And Mayne Pharma's Vaginal Contraceptive Ring Accepted For Filing By FDA​

* MITHRA AND MAYNE PHARMA'S VAGINAL CONTRACEPTIVE RING ACCEPTED FOR FILING BY FDA

BRIEF-Mithra Analysis Across A Range Of Parameters Points To Limited Hemostatic Impact For Estelle

* ANALYSIS ACROSS A RANGE OF PARAMETERS POINTS TO LIMITED HEMOSTATIC IMPACT FOR ESTELLE®,

BRIEF-Mithra Announces Very Promising Hemostasis Results For Estelle​

* MITHRA PHARMACEUTICALS SA - MITHRA ANNOUNCES VERY PROMISING HEMOSTASIS RESULTS FOR ESTELLE®

BRIEF-Mithra Pharmaceuticals Announces Last Subject Completes Donesta Phase II Study​

* MITHRA ANNOUNCES LAST SUBJECT COMPLETES DONESTA® PHASE II STUDY

BRIEF-Mithra Pharmaceuticals And Adamed Sign Commercialization Agreement For Myring™ In The Czech Republic

* MITHRA AND ADAMED SIGN COMMERCIALIZATION AGREEMENT FOR MYRING™ IN THE CZECH REPUBLIC

BRIEF-Mithra Pharmaceuticals Announces Injectables Agreement With GSP

* MITHRA CLOSES CONTRACTS WITH LEADING GENERICS PLAYER GSP FOR DEVELOPMENT AND SUPPLY OF 4 HORMONAL INJECTABLES

BRIEF-Mithra Pharmaceuticals Finalizes Estelle Contract With Libbs

* FINALIZES ESTELLE CONTRACT WITH BRAZILIAN WOMEN’S HEALTH LEADER LIBBS

BRIEF-Mithra Announces Valorization Of French Subsidiary

* SUCCESSFULLY DIVESTED ITS FRENCH AFFILIATE, MITHRA FRANCE

BRIEF-Mithra Pharmaceuticals Announces Update On Clinical Study Progress For Estelle And Donesta

* ANNOUNCES AN UPDATE ON THE CLINICAL STUDY PROGRESS FOR ESTELLE AND DONESTA

BRIEF-Mithra Pharmaceuticals announces 36-month shelf life extension for Tibelia​

* MITHRA ANNOUNCES 36-MONTH SHELF LIFE EXTENSION FOR TIBELIA

BRIEF-Mithra Pharmaceuticals ‍completes recruitment for Estelle Phase III study in US and Canada​

* COMPLETES RECRUITMENT FOR ESTELLE® PHASE III STUDY IN US AND CANADA

BRIEF-Mithra Pharmaceuticals' application for Tibelia marketing authorization accepted by Health Canada

* MITHRA’S MARKETING AUTHORIZATION APPLICATION FOR TIBELIA ACCEPTED BY HEALTH CANADA

BRIEF-Mithra Pharmaceuticals signs commercial agreement with Libbs

* MITHRA PHARMACEUTICALS SA - MITHRA SIGNS COMMERCIAL AGREEMENT WITH BRAZILIAN LEADER IN WOMEN’S HEALTH LIBBS FOR ESTELLE® IN BRAZIL

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up